PDE5 Inhibitors

Phosphodiesterase type 5 (PDE5) inhibitors are the first-line pharmacological treatment for erectile dysfunction. By inhibiting PDE5, they prevent the degradation of cyclic GMP, enhancing nitric oxide–mediated smooth muscle relaxation in the corpus cavernosum and facilitating erection in response to sexual stimulation. Available agents include sildenafil, tadalafil, vardenafil, and avanafil, with differences in onset, duration, and food/alcohol interactions.

Indications

Coming soon.

Mechanism & Agents

Coming soon.

Key Steps

Coming soon.

Outcomes & Evidence

Coming soon.

References

Coming soon.